Monserrat Sanz, J.; Bohórquez, C.; Gómez, A.M.; Movasat, A.; Pérez, A.; Ruíz, L.; Diaz, D.; Sánchez, A.I.; Albarrán, F.; Sanz, I.;
et al. Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients. Int. J. Mol. Sci. 2020, 21, 6847.
https://doi.org/10.3390/ijms21186847
AMA Style
Monserrat Sanz J, Bohórquez C, Gómez AM, Movasat A, Pérez A, Ruíz L, Diaz D, Sánchez AI, Albarrán F, Sanz I,
et al. Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients. International Journal of Molecular Sciences. 2020; 21(18):6847.
https://doi.org/10.3390/ijms21186847
Chicago/Turabian Style
Monserrat Sanz, Jorge, Cristina Bohórquez, Ana Maria Gómez, Atusa Movasat, Ana Pérez, Lucía Ruíz, David Diaz, Ana Isabel Sánchez, Fernando Albarrán, Ignacio Sanz,
and et al. 2020. "Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients" International Journal of Molecular Sciences 21, no. 18: 6847.
https://doi.org/10.3390/ijms21186847
APA Style
Monserrat Sanz, J., Bohórquez, C., Gómez, A. M., Movasat, A., Pérez, A., Ruíz, L., Diaz, D., Sánchez, A. I., Albarrán, F., Sanz, I., & Álvarez-Mon, M.
(2020). Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients. International Journal of Molecular Sciences, 21(18), 6847.
https://doi.org/10.3390/ijms21186847